Dermira, Inc. (DERM) CEO Sells $137,600.00 in Stock
Dermira, Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $27.52, for a total value of $137,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Thomas G. Wiggans also recently made the following trade(s):
- On Monday, September 18th, Thomas G. Wiggans sold 9,500 shares of Dermira stock. The stock was sold at an average price of $27.51, for a total value of $261,345.00.
Shares of Dermira, Inc. (DERM) traded up $2.20 during mid-day trading on Friday, hitting $29.08. The stock had a trading volume of 447,985 shares, compared to its average volume of 435,675. The company has a debt-to-equity ratio of 0.75, a quick ratio of 24.43 and a current ratio of 24.43.
Dermira (NASDAQ:DERM) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.04). The business had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. research analysts expect that Dermira, Inc. will post -4.15 EPS for the current fiscal year.
WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/dermira-inc-derm-ceo-sells-137600-00-in-stock.html.
DERM has been the subject of several recent analyst reports. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Needham & Company LLC reiterated a “buy” rating and set a $46.00 price objective on shares of Dermira in a research note on Tuesday, July 18th. Mizuho reiterated a “buy” rating and set a $43.00 price objective (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Cantor Fitzgerald reiterated a “buy” rating and set a $45.00 price objective on shares of Dermira in a research note on Tuesday, September 26th. Finally, BidaskClub upgraded Dermira from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $44.40.
Hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its holdings in shares of Dermira by 2,220.7% during the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 3,975 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Dermira by 66.8% during the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,203 shares during the last quarter. KCG Holdings Inc. bought a new stake in shares of Dermira during the first quarter worth $215,000. Legal & General Group Plc grew its holdings in shares of Dermira by 16.3% during the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 963 shares during the last quarter. Finally, Ardsley Advisory Partners bought a new stake in shares of Dermira during the second quarter worth $291,000. Institutional investors own 97.67% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.